Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Journal Mobile Options
Table of Contents
Vol. 28, No. 6, 2007
Issue release date: April 2008
Section title: Research Article
Tumor Biol 2007;28:318–326
(DOI:10.1159/000121405)

Overexpression of Orphan Receptor Tyrosine Kinase Ror1 as a Putative Tumor-Associated Antigen in Iranian Patients with Acute Lymphoblastic Leukemia

Shabani M.a · Asgarian Omran H.a · Jeddi-Tehrani M.b, g · Vossough P.d · Faranoush M.d · Sharifian R.A.e · Toughe G.R.e · Kordmahin M.e · Khoshnoodi J.a · Roohi A.a · Tavoosi N.c · Mellstedt H.g · Rabbani H.c, g · Shokri F.a, b, f
aDepartment of Immunology, School of Public Health, Medical Sciences/University of Tehran, bMonoclonal Antibody Research Center and cDepartment of Reproductive Immunology, Reproductive Biotechnology Research Center, Avesina Research Institute, dClinic of Hematology, Ali-Asghar Hospital, Faculty of Medicine, Iran University of Medical Sciences, eClinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Medical Sciences/University of Tehran, fNational Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran, and gImmune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00
EUR 35.00
USD 39.00

Select

Rent/Cloud

  • Rent For 48h To view
  • Buy Cloud Access For unlimited viewing via different devices
  • Synchronizing In the ReadCube Cloud
  • Printing And saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com

The final prices may differ from the prices shown due To specifics Of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: June 01, 2007
Accepted: October 30, 2007
Published online: March 20, 2008
Issue release date: April 2008

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 2

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

Receptor tyrosine kinases (RTKs) are a group of enzymes involved in a variety of physiological and pathological processes. The human Ror1 is a member of the RTK family with unknown ligand and biological function. Overexpression of Ror1 has recently been reported in B-cell chronic lymphocytic leukemia. The aim of this study was to explore the expression profile of Ror1 in acute lymphoblastic leukemia (ALL) cells. Therefore, leukemic cells were isolated from the bone marrow and/or peripheral blood (PB) of 57 ALL patients. Immunophenotyping was performed by flow cytometry and mRNA expression was detected by RT-PCR. Overexpression of Ror1 mRNA was detected in 23 of 57 (40%) ALL patients. A similar expression pattern was observed in ALL cell lines, with 4 of 12 (33%) being positive. Stimulation of normal PB mononuclear cells with pokeweed mitogen and phorbol myristate acetate induced substantially higher Ror1 mRNA expression compared to unstimulated cultured cells. There has been neither a significant association between Ror1 expression and the immunophenotypic profile of the leukemic cells, nor with other clinical or hematological features of the patients. In conclusion, our findings propose Ror1 as a new tumor-associated antigen and a potential tool for targeted immunotherapy and monitoring of minimal residual disease in ALL.

© 2008 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: June 01, 2007
Accepted: October 30, 2007
Published online: March 20, 2008
Issue release date: April 2008

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 2

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.